-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
During -X- _ O
the -X- _ O
acute -X- _ O
phase -X- _ O
of -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
, -X- _ O
mononuclear -X- _ O
cells -X- _ O
infiltration -X- _ O
, -X- _ O
alveolar -X- _ O
cell -X- _ O
desquamation -X- _ O
and -X- _ O
hyaline -X- _ O
membrane -X- _ O
formation -X- _ O
have -X- _ O
been -X- _ O
described -X- _ O
, -X- _ O
together -X- _ O
with -X- _ O
dysregulation -X- _ O
of -X- _ O
plasma -X- _ O
cytokine -X- _ O
levels. -X- _ O
Persistent -X- _ O
high-resolution -X- _ O
computed -X- _ O
tomography -X- _ O
( -X- _ O
HRCT -X- _ O
) -X- _ O
abnormalities -X- _ O
occur -X- _ O
in -X- _ O
SARS -X- _ B-Patient
patients -X- _ I-Patient
up -X- _ I-Patient
to -X- _ I-Patient
40 -X- _ I-Patient
days -X- _ I-Patient
after -X- _ I-Patient
recovery. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
To -X- _ O
determine -X- _ O
further -X- _ O
the -X- _ O
time -X- _ O
course -X- _ O
of -X- _ O
recovery -X- _ O
of -X- _ O
lung -X- _ O
inflammation -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ B-Intervention
the -X- _ I-Intervention
HRCT -X- _ I-Intervention
and -X- _ I-Intervention
inflammatory -X- _ I-Intervention
profiles -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
coronavirus -X- _ I-Intervention
persistence -X- _ I-Intervention
in -X- _ I-Intervention
bronchoalveolar -X- _ I-Intervention
lavage -X- _ I-Intervention
fluid -X- _ I-Intervention
( -X- _ I-Intervention
BALF -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
12 -X- _ I-Intervention
patients -X- _ I-Intervention
at -X- _ I-Intervention
recovery -X- _ I-Intervention
at -X- _ I-Intervention
60 -X- _ I-Intervention
and -X- _ I-Intervention
90 -X- _ I-Intervention
days. -X- _ I-Intervention
RESULTS -X- _ O
: -X- _ O
At -X- _ O
60 -X- _ O
days -X- _ O
, -X- _ O
compared -X- _ O
to -X- _ O
normal -X- _ O
controls -X- _ O
, -X- _ O
SARS -X- _ B-Outcome
patients -X- _ I-Outcome
had -X- _ I-Outcome
increased -X- _ I-Outcome
cellularity -X- _ I-Outcome
of -X- _ I-Outcome
BALF -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
alveolar -X- _ I-Outcome
macrophages -X- _ I-Outcome
( -X- _ I-Outcome
AM -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
CD8 -X- _ I-Outcome
cells. -X- _ I-Outcome
HRCT -X- _ I-Outcome
scores -X- _ I-Outcome
were -X- _ I-Outcome
increased -X- _ I-Outcome
and -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
T-cell -X- _ I-Outcome
numbers -X- _ I-Outcome
and -X- _ I-Outcome
their -X- _ I-Outcome
subpopulations -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
inversely -X- _ I-Outcome
with -X- _ I-Outcome
CD4 -X- _ I-Outcome
/ -X- _ I-Outcome
CD8 -X- _ I-Outcome
ratio. -X- _ I-Outcome
TNF-Î± -X- _ I-Outcome
, -X- _ I-Outcome
IL-6 -X- _ I-Outcome
, -X- _ I-Outcome
IL-8 -X- _ I-Outcome
, -X- _ I-Outcome
RANTES -X- _ I-Outcome
and -X- _ I-Outcome
MCP-1 -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
increased. -X- _ I-Outcome
Viral -X- _ I-Outcome
particles -X- _ I-Outcome
in -X- _ I-Outcome
AM -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
by -X- _ I-Outcome
electron -X- _ I-Outcome
microscopy -X- _ I-Outcome
in -X- _ I-Outcome
7 -X- _ I-Outcome
of -X- _ I-Outcome
12 -X- _ I-Outcome
SARS -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
high -X- _ I-Outcome
HRCT -X- _ I-Outcome
score. -X- _ I-Outcome
On -X- _ O
day -X- _ O
90 -X- _ O
, -X- _ O
HRCT -X- _ B-Outcome
scores -X- _ I-Outcome
improved -X- _ I-Outcome
significantly -X- _ I-Outcome
in -X- _ I-Outcome
10 -X- _ I-Outcome
of -X- _ I-Outcome
12 -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
normalization -X- _ I-Outcome
of -X- _ I-Outcome
BALF -X- _ I-Outcome
cell -X- _ I-Outcome
counts -X- _ I-Outcome
in -X- _ I-Outcome
6 -X- _ I-Outcome
of -X- _ I-Outcome
12 -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
repeat -X- _ I-Outcome
bronchoscopy. -X- _ I-Outcome
Pulse -X- _ I-Outcome
steroid -X- _ I-Outcome
therapy -X- _ I-Outcome
and -X- _ I-Outcome
prolonged -X- _ I-Outcome
fever -X- _ I-Outcome
were -X- _ I-Outcome
two -X- _ I-Outcome
independent -X- _ I-Outcome
factors -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
delayed -X- _ I-Outcome
resolution -X- _ I-Outcome
of -X- _ I-Outcome
pneumonitis -X- _ I-Outcome
, -X- _ O
in -X- _ O
this -X- _ O
non-randomized -X- _ O
, -X- _ O
retrospective -X- _ O
analysis. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
Resolution -X- _ B-Outcome
of -X- _ I-Outcome
pneumonitis -X- _ I-Outcome
is -X- _ I-Outcome
delayed -X- _ I-Outcome
in -X- _ O
some -X- _ O
patients -X- _ B-Patient
during -X- _ I-Patient
SARS -X- _ I-Patient
recovery -X- _ I-Patient
and -X- _ O
may -X- _ O
be -X- _ O
associated -X- _ O
with -X- _ O
delayed -X- _ B-Outcome
clearance -X- _ I-Outcome
of -X- _ I-Outcome
coronavirus -X- _ I-Outcome
, -X- _ O
Complete -X- _ O
resolution -X- _ B-Outcome
may -X- _ I-Outcome
occur -X- _ I-Outcome
by -X- _ I-Outcome
90 -X- _ I-Outcome
days -X- _ I-Outcome
or -X- _ I-Outcome
later -X- _ I-Outcome
. -X- _ O

